This HTML5 document contains 57 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n13http://linked.opendata.cz/resource/drugbank/drug/DB01604/identifier/drugbank/
n18http://linked.opendata.cz/resource/mesh/concept/
n15http://linked.opendata.cz/resource/drugbank/drug/DB01604/identifier/chemspider/
n16http://bio2rdf.org/drugbank:
n14http://linked.opendata.cz/resource/drugbank/drug/DB01604/identifier/chebi/
admshttp://www.w3.org/ns/adms#
n19http://linked.opendata.cz/resource/drugbank/drug/DB01604/identifier/wikipedia/
n12http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n20http://linked.opendata.cz/resource/drugbank/drug/DB01604/identifier/pharmgkb/
owlhttp://www.w3.org/2002/07/owl#
n17http://linked.opendata.cz/ontology/mesh/
n8http://linked.opendata.cz/ontology/drugbank/
n10http://linked.opendata.cz/resource/drugbank/drug/DB01604/identifier/kegg-compound/
n9http://linked.opendata.cz/resource/drugbank/property/
n4http://linked.opendata.cz/resource/drugbank/drug/DB01604/identifier/pubchem-compound/
xsdhhttp://www.w3.org/2001/XMLSchema#
n5http://linked.opendata.cz/resource/drugbank/drug/DB01604/identifier/pubchem-substance/
n7http://linked.opendata.cz/resource/atc/
n6http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01604
rdf:type
n8:Drug
n8:description
Pivalate ester analog of ampicillin.
n8:generalReferences
# Albertson TE, Louie S, Chan AL: The diagnosis and treatment of elderly patients with acute exacerbation of chronic obstructive pulmonary disease and chronic bronchitis. J Am Geriatr Soc. 2010 Mar;58(3):570-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20398122 # Chanteux H, Van Bambeke F, Mingeot-Leclercq MP, Tulkens PM: Accumulation and oriented transport of ampicillin in Caco-2 cells from its pivaloyloxymethylester prodrug, pivampicillin. Antimicrob Agents Chemother. 2005 Apr;49(4):1279-88. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15793098
n8:group
approved
n8:halfLife
Approximately 1 hour.
n8:indication
or the treatment of respiratory tract infections (including acute bronchitis, acute exacerbations of chronic bronchitis and pneumonia); ear, nose and throat infections; gynecological infections; urinary tract infections (including acute uncomplicated gonococcal urethritis) when caused by non penicillinase-producing susceptible strains of the following organisms: gram-positive organisms, e.g., streptococci, pneumococci and staphylococci; gram-negative organisms, e.g., H. influenzae, N. gonorrhoeae, E. coli, P. mirabilis.
owl:sameAs
n12:DB01604 n16:DB01604
dcterms:title
Pivampicillin
adms:identifier
n4:33478 n5:46505340 n10:C11750 n13:DB01604 n14:8255 n15:30899 n19:Pivampicillin n20:PA164776912
n8:mechanismOfAction
Ampicillin (the active metabolite of pivampicillin) has a bactericidal action resulting from inhibition of cell wall mucopeptide biosynthesis.
n8:synonym
Pivaloylampicillin Pivaloyloxymethyl ampicillinate Pivampicillinum Ampicillin pivaloyloxymethyl ester Pivampicilline Pivampicilina
n8:foodInteraction
Take without regard to meals.
n17:hasConcept
n18:M0016927
n8:IUPAC-Name
n9:271B5B07-363D-11E5-9242-09173F13E4C5
n8:InChI
n9:271B5B0D-363D-11E5-9242-09173F13E4C5
n8:Molecular-Formula
n9:271B5B0C-363D-11E5-9242-09173F13E4C5
n8:Molecular-Weight
n9:271B5B09-363D-11E5-9242-09173F13E4C5
n8:Monoisotopic-Weight
n9:271B5B0A-363D-11E5-9242-09173F13E4C5
n8:SMILES
n9:271B5B0B-363D-11E5-9242-09173F13E4C5
n8:Water-Solubility
n9:271B5B05-363D-11E5-9242-09173F13E4C5
n8:logP
n9:271B5B03-363D-11E5-9242-09173F13E4C5 n9:271B5B06-363D-11E5-9242-09173F13E4C5
n8:logS
n9:271B5B04-363D-11E5-9242-09173F13E4C5
n6:hasATCCode
n7:J01CA02
n8:H-Bond-Acceptor-Count
n9:271B5B13-363D-11E5-9242-09173F13E4C5
n8:H-Bond-Donor-Count
n9:271B5B14-363D-11E5-9242-09173F13E4C5
n8:InChIKey
n9:271B5B0E-363D-11E5-9242-09173F13E4C5
n8:Polar-Surface-Area--PSA-
n9:271B5B0F-363D-11E5-9242-09173F13E4C5
n8:Polarizability
n9:271B5B11-363D-11E5-9242-09173F13E4C5
n8:Refractivity
n9:271B5B10-363D-11E5-9242-09173F13E4C5
n8:Rotatable-Bond-Count
n9:271B5B12-363D-11E5-9242-09173F13E4C5
n8:absorption
Absorbed following oral administration.
n8:affectedOrganism
Enteric bacteria and other eubacteria
n8:casRegistryNumber
33817-20-8
n8:category
n8:Bioavailability
n9:271B5B19-363D-11E5-9242-09173F13E4C5
n8:Ghose-Filter
n9:271B5B1B-363D-11E5-9242-09173F13E4C5
n8:MDDR-Like-Rule
n9:271B5B1C-363D-11E5-9242-09173F13E4C5
n8:Number-of-Rings
n9:271B5B18-363D-11E5-9242-09173F13E4C5
n8:Physiological-Charge
n9:271B5B17-363D-11E5-9242-09173F13E4C5
n8:Rule-of-Five
n9:271B5B1A-363D-11E5-9242-09173F13E4C5
n8:Traditional-IUPAC-Name
n9:271B5B08-363D-11E5-9242-09173F13E4C5
n8:pKa--strongest-acidic-
n9:271B5B15-363D-11E5-9242-09173F13E4C5
n8:pKa--strongest-basic-
n9:271B5B16-363D-11E5-9242-09173F13E4C5